Enhanced PPAR-γ expression may correlate with the development of Barrett's esophagus and esophageal adenocarcinoma

Oncology Research

Volumn 19, Issue 3-4, 2011, Pages 141-147

  Wang, Wen ^a   Wang, Rong ^a   Zhang, Zhijian ^a   Li, Dazhou ^a   Yu, Yinghao ^a  

^a FUZHOU GENERAL HOSPITAL   (China)

Author keywords

Barrett's esophagus; Clinicopathology; Esophageal adenocarcinoma; Immunohistochemistry; Peroxisome proliferator activated receptor (PPAR )

Indexed keywords

MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CELL MATURATION; CELL NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS MUCOSA; FEMALE; GOBLET CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS EPITHELIUM;

EID: 79952390934     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504011X12935427587849     Document Type: Article

References (30)

1. DeMeester, S. R.; DeMeester, T. R. Columnar mucosa and intestinal metaplasia of the esophagus: Fifty years of controversy. Ann. Surg. 231:303-321; 2000.
2. Reid, B. J.; Li, X.; Galipeau, P. C.; Vaughan, T. L. Barrett's oesophagus and oesophageal adenocarcinoma: Time for a new synthesis. Nat. Rev. Cancer 10:87-101; 2010.
3. D'Amico, T. A. Outcomes after surgery for esophageal cancer. Gastrointest. Cancer Res. 1:188-196; 2007.
4. Altorki, N. K.; Girardi, L.; Skinner, D. B. En bloc esophagectomy improves survival for stage III esophageal cancer. J. Thorac. Cardiovasc. Surg. 114:948-956; 1997.
5. Fajas, L.; Debril, M. B.; Auwerx, J. Peroxisome proliferator- activated receptor-gamma: From adipogenesis to carcinogenesis. J. Mol. Endocrinol. 27:1-9; 2001.
6. Tontonoz, P.; Singer, S.; Forman, B. M.; Sarraf, P.; Fletcher, J. A.; Fletcher, C. D.; Brun, R. P.; Mueller, E.; Altiok, S.; Oppenheim, H. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc. Natl. Acad. Sci. USA 94:237-241; 1997.
7. Mueller, E.; Sarraf, P.; Tontonoz, P.; Evans, R. M.; Martin, K. J.; Zhang, M.; Fletcher, C.; Singer, S.; Spiegelman, B. M. Terminal differentiation of human breast cancer through PPAR gamma. Mol. Cell 1:465-470; 1998.
8. Walczak, R.; Tontonoz, P. PPARadigms and PPARadoxes: Expanding roles for PPARgamma in the control of lipid metabolism. J. Lipid. Res. 43:177-186; 2002.
9. Debril, M. B.; Renaud, J. P.; Fajas, L.; Auwerx, J. The pleiotropic functions of peroxisome proliferator-activated receptor gamma. J. Mol. Med. 79:30-47; 2001.
10. Elstner, E.; Muller, C.; Koshizuka, K.; Williamson, E. A.; Park, D.; Asou, H.; Shintaku, P.; Said, J. W.; Heber, D.; Koeffler, H. P. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. USA 95: 8806-8811; 1998.
11. Kubota, T.; Koshizuka, K.; Williamson, E. A.; Asou, H.; Said, J. W.; Holden, S.; Miyoshi, I.; Koeffler, H. P. Li-gand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 58:3344-3352; 1998.
12. Butler, R.; Mitchell, S. H.; Tindall, D. J.; Young, C. Y. Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor gamma ligand, 15-deoxy-delta12,14- prostaglandin J2. Cell Growth Differ. 11:49-61; 2000.
13. Motomura, W.; Okumura, T.; Takahashi, N.; Obara, T.; Kohgo, Y. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells. Cancer Res. 60:5558-5564; 2000.
14. Eibl, G.; Wente, M. N.; Reber, H. A.; Hines, O. J. Peroxisome proliferator-activated receptor gamma induces pancreatic cancer cell apoptosis. Biochem. Biophys. Res. Commun. 287:522-529; 2001.
15. Itami, A.; Watanabe, G.; Shimada, Y.; Hashimoto, Y.; Kawamura, J.; Kato, M.; Hosotani, R.; Imamura, M. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth of pancreatic cancers both in vitro and in vivo. Int. J. Cancer 94:370-376; 2001.
16. Chang, C. Y.; Lee, Y. C.; Lee, C. T. The application of Prague C and M criteria in the diagnosis of Barrett's esophagus in an ethnic Chinese population. Am. J. Gastroenterol. 104:13-20; 2009.
17. D'Amico, T. A. Surgery for esophageal cancer. Gastrointest. Cancer Res. 2(4 Suppl.):S6-9; 2008.
18. Becker, L.; Huang, Q.; Mashimo, H. Lgr5, an intestinal stem cell marker, is abnormally expressed in Barrett's esophagus and esophageal adenocarcinoma. Dis. Esophagus 23:168-174; 2010.
19. Leodolter, A. Barrett's esophagus and cytokine polymorphisms-confusion about the content in the abstract/results section compared to the table given in a recent manuscript. Am. J. Gastroenterol. 100:2814; 2005.
20. Ricote, M.; Li, A. C.; Willson, T. M.; Kelly, C. J.; Glass, C. K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391:79-82; 1998.
21. Jiang, C.; Ting, A. T.; Seed, B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82-86; 1998.
22. Brockman, J. A.; Gupta, R. A.; Dubois, R. N. Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 115:1049-1055; 1998.
23. Kitamura, S.; Miyazaki, Y.; Shinomura, Y.; Kondo, S.; Kanayama, S.; Matsuzawa, Y. Peroxisome proliferatoractivated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. Jpn. J. Cancer Res. 90:75-80; 1999.
24. Takahashi, N.; Okumura, T.; Motomura, W.; Fujimoto, Y.; Kawabata, I.; Kohgo, Y. Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett. 455:135-139; 1999.
25. Sato, H.; Ishihara, S.; Kawashima, K.; Moriyama, N.; Suetsugu, H.; Kazumori, H.; Okuyama, T.; Rumi, M. A.; Fukuda, R.; Nagasue, N.; et al. Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br. J. Cancer 83:1394-1400; 2000.
26. Altiok, S.; Xu, M.; Spiegelman, B. M. PPARgamma induces cell cycle withdrawal: Inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev. 11:1987-1998; 1997.
27. Takashima, T.; Fujiwara, Y.; Higuchi, K.; Arakawa, T.; Yano, Y.; Hasuma, T.; Otani, S. PPAR-gamma ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity. Int. J. Oncol. 19: 465-471; 2001.
28. Takahashi, H.; Fujita, K.; Fujisawa, T.; Yonemitsu, K.; Tomimoto, A.; Ikeda, I.; Yoneda, M.; Masuda, T.; Schaefer, K.; Saubermann, L. J. et al. Inhibition of peroxisome proliferator-activated receptor gamma activity in esophageal carcinoma cells results in a drastic decrease of invasive properties. Cancer Sci. 97:854-860; 2006.
29. Takashima, T.; Fujiwara, Y.; Hamaguchi, M.; Sasaki, E.; Tominaga, K.; Watanabe, T.; Oshitani, N.; Higuchi, K.; Arakawa, T. Relationship between peroxisome proliferator- activated receptor-gamma expression and differentia- tion of human esophageal squamous cell carcinoma. Oncol. Rep. 13:601-606; 2005.
30. Pandhare, J.; Cooper, S. K.; Phang, J. M. Proline oxidase, a proapoptotic gene, is induced by troglitazone: Evidence for both peroxisome proliferator-activated receptor gamma-dependent and -independent mechanisms. J. Biol. Chem. 281:2044-2052; 2006.